Exceptional Response of Nelson's Syndrome to Pasireotide LAR in the Long-Term Follow-up of 9 Years

Exp Clin Endocrinol Diabetes. 2021 Oct;129(10):776-778. doi: 10.1055/a-1158-9214. Epub 2020 Nov 12.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Female
  • Follow-Up Studies
  • Humans
  • Middle Aged
  • Nelson Syndrome / drug therapy*
  • Somatostatin / administration & dosage
  • Somatostatin / analogs & derivatives*
  • Somatostatin / pharmacology
  • Treatment Outcome

Substances

  • Somatostatin
  • pasireotide